(Drug Creation Process: Learn and Confirm, a new Paradigm for Clinical Development at Wyeth)
Pharmaceuticals - a knowledge driven industry:
Pharmaceuticals happen to be one of the most extremely 'Knowledge Driven' industries that is always in a state of change. Human, animal, and environmental health remains the topmost interest of the society. Diversities in life form and infections render grave challenges to the formulation of particular and targeted solutions. Drug discovery is an elaborate process needing almost a decade at a cost of 300 million U.S. dollars to get a new drug to the market. Hence the long waiting period in between 'learning', knowledge generation' and its changeover to 'value added knowledge' requires the building of Proprietary Knowledge' that is of immense value in setting up and maintaining a worldwide creative gesture. One of our major competitors Merck and Co holds expertise in medicinal preparations & chemistry of N-Heterocyclics liquid crystalline materials having saturated or unsaturated non-aromatic rings. Novartis, our next competitor is a global leader in chemistry of N-based hetrocyclics, carbohydrates, proteins, peptides, and other diverse condensed ring systems. Besides, they have leadership position in fermentation as also enzyme-based processes for preparation of organic compounds, tissue culture and a minor business in recombinant DNA technology (Global Pharmaceutical Industry: Intellectual Wealth and Asset Protection)
Product Life Cycle Management -- a sunrise business process for pharmaceutical industry:
The global pharma industry is seeing speedy progression in processes and technology and computerization is coming to hold a vital constituent part in majority of the manufacturing processes. Due to rigid regulatory standards and rising costs, pharma companies prefer to hand over their manufacturing processes to Contract Manufacturing Organization -- CMOs as a part of outsourcing so as to enhance productivity. (Global Pharmaceutical Contract Manufacturing Markets) a new domain that is arrived on the shores of pharmaceutical, and I am sure that Wyeth will immensely benefit from this which is Product Life Cycle Management -- PLM which aligns with the pharma industry's business processes. PLM deals with the challenges of managing a group of hundreds of drug candidates, from a collection of different R&D facilities and manufacturing plants across the world. Augmenting to the business drivers for investing in PLM is the mounting pressure by the regulatory agencies that stresses on adherence to ensure drug safety. (Pharma product lifecycle management gains momentum)
Thanking you,
Yours truly,
ABC
Senior Consultant,
Pharmaceutical and Biogenics
Exhibit -I
Financial Highlights
Items
Year Ended December 31 in thousands except per share amounts)
Net Revenue
Net Income
Diluted Earnings per share
Dividends per Common share
Total Assets
Stockholders Equity
Exhibit -II
Selected Financial Data
Dollar amounts in thousands except per share amounts)
Year Ended December 31, 2006 2005 2004 2003
Net revenue $20,350,655 $18,755,790 $17,358,028 $15,850,632
Research and development expenses 3,109,060 2,749,390 2,460,610 2,093,533
Net income 4,196,706 3,656,298 1,233,997 2,051,192
Diluted earnings per share 3.08 2.70 0.91 1.54
Dividends per common share 1.01 0.9400 0.9200 0.9200
Capital expenditures 1,289,784 1,081,291 1,255,275 1,908,661
Total assets $36,478,715 $35,841,126 $33,629,704 $31,031,922
Number of common stockholders 47,314 50,648 54,301 59,181
Number of employees at year end 50,060 49,732 51,401 52,385
Wages and salaries $3,488,510 $3,434,476 $3,280,328 $3,003,555
Company Data by Reportable Segment
In millions)
Year Ended December 31, 2006 2005 2004 2003
Net Revenue from Customers
Pharmaceuticals $16,884.2 $15,321.1 $13,964.1 $12,622.7
Consumer Healthcare 2,530.2-2,553.9-2,557.4-2, 434.5
Animal Health 936.3 880.8 836.5 793.4
Consolidated total $20,350.7 $18,755.8 $17,358.0 $15,850.6
Income (Loss) before Income Taxes
Pharmaceuticals $5,186.4 $4,544.9 $4,040.1 $3,798.5
Consumer Healthcare 516.2 574.3 578.6 592.4
Animal Health 163.7 139.4 134.8 127.4
Corporate (436.4) (478.0) (4,883.3) (2,156.7)
Consolidated total $5,429.9 $4,780.6...
Direct to Consumer Advertising HISTORY OF DRUG ADVERTISING THE DTC ADVERTISING PHENOMENON CREATING DEMAND DECEPTIVE ADVERTISING - A WOLF IN SHEEP'S CLOTHING CAUSE OF DEATH PROFIT UTILIZATION, PRICING, AND DEMOGRAPHICS LEGISLATION, POLITICS AND PATENTS LEGISLATIVE INITIATIVES REGARDING DTC RECALLED and/or DEADLY DRUGS In order to provide the most efficient method of evaluation, the study will utilize existing stores of qualitative and quantitative data from reliable sources, such as U.S. Government statistical references, University studies, and the studies and publications of non-profit
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now